Skip to main content
Premium Trial:

Request an Annual Quote

New York State OKs Pathwork Dx's Tissue of Origin Test

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pathwork Diagnostics today announced it has received approval from the New York State Department of Health to offer its Tissue of Origin testing service.

As a result the Redwood, Calif., company will be able to offer the service, which it said is the only FDA-cleared tissue of origin testing service in New York state.

The test helps identify the origin of challenging tumors and increases pathologist and oncologist confidence in the diagnosis of cancer, according to Pathwork. The test uses small amounts of formalin fixed, paraffin-embedded tumor tissue and measures gene expression levels of more than 2,000 genes. It received FDA clearance in June for use with FFPE tissues and is the only FDA-cleared molecular diagnostic test for tissue of origin.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.